Follow the people · Insider
Donald Notman
Donald Notman files insider transactions with the SEC as a chief operating officer of Ocular Therapeutix (OCUL). We hold 4 disclosed purchases and sales filed since 3 October 2017, 1 of them in the last 90 days.
- Files forOCUL
- Disclosed buys and sells4 in all, 1 in the last 90 days
- Last disclosure2 September 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 2 October 2017 — 31 August 2026Chief Operating Officer · Ocular Therapeutix (OCUL)35 Form 4 lines · source: SEC Form 4
Everything they disclosed
35 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 1,099 shares of Ocular TherapeutixSEC Form 42 September 2026Common Stock · traded 31 August 2026 · filed 2 September 2026
- ▼ sold on the open market 11,446 shares of Ocular TherapeutixSEC Form 417 February 2026Common Stock · traded 12 February 2026 · filed 17 February 2026
- ▼ sold on the open market 11,446 shares of Ocular TherapeutixSEC Form 417 February 2026Common Stock · traded 12 February 2026 · filed 17 February 2026
- ▼ sold on the open market 5,455 shares of Ocular TherapeutixSEC Form 44 February 2026Common Stock · traded 2 February 2026 · filed 4 February 2026
- ▼ sold on the open market 6,035 shares of Ocular TherapeutixSEC Form 44 February 2026Common Stock · traded 4 February 2026 · filed 4 February 2026
- ▼ sold on the open market 5,455 shares of Ocular TherapeutixSEC Form 44 February 2026Common Stock · traded 2 February 2026 · filed 4 February 2026
- ▼ sold on the open market 6,035 shares of Ocular TherapeutixSEC Form 44 February 2026Common Stock · traded 4 February 2026 · filed 4 February 2026
- was granted 79,112 shares of Ocular TherapeutixSEC Form 46 January 2026Common Stock · traded 2 January 2026 · filed 6 January 2026
- was granted 240,932 shares of Ocular Therapeutix (a derivative holding)SEC Form 46 January 2026Stock Option (Right to Buy) · traded 2 January 2026 · filed 6 January 2026
- was granted 240,932 shares of Ocular Therapeutix (a derivative holding)SEC Form 46 January 2026Stock Option (Right to Buy) · traded 2 January 2026 · filed 6 January 2026
- was granted 79,112 shares of Ocular TherapeutixSEC Form 46 January 2026Common Stock · traded 2 January 2026 · filed 6 January 2026
- ▼ sold on the open market 1,066 shares of Ocular TherapeutixSEC Form 44 September 2025Common Stock · traded 2 September 2025 · filed 4 September 2025
- was granted 344,115 shares of Ocular Therapeutix (a derivative holding)SEC Form 413 February 2025Stock Option (Right to Buy) · traded 11 February 2025 · filed 13 February 2025
- was granted 115,000 shares of Ocular TherapeutixSEC Form 413 February 2025Common Stock · traded 11 February 2025 · filed 13 February 2025
- ▼ sold on the open market 6,301 shares of Ocular TherapeutixSEC Form 44 February 2025Common Stock · traded 31 January 2025 · filed 4 February 2025
- ▼ sold on the open market 11,119 shares of Ocular TherapeutixSEC Form 44 February 2025Common Stock · traded 4 February 2025 · filed 4 February 2025
- was granted 33,602 shares of Ocular Therapeutix (a derivative holding)SEC Form 43 September 2024Stock Option (Right to Buy) · traded 29 August 2024 · filed 3 September 2024
- was granted 11,034 shares of Ocular TherapeutixSEC Form 43 September 2024Common Stock · traded 29 August 2024 · filed 3 September 2024
- was granted 185,000 shares of Ocular Therapeutix (a derivative holding)SEC Form 46 February 2024Stock Option (Right to Buy) · traded 3 February 2024 · filed 6 February 2024
- was granted 61,636 shares of Ocular TherapeutixSEC Form 46 February 2024Common Stock · traded 3 February 2024 · filed 6 February 2024
- ▼ sold on the open market 6,212 shares of Ocular TherapeutixSEC Form 46 February 2024Common Stock · traded 5 February 2024 · filed 6 February 2024
- ▼ sold on the open market 6,433 shares of Ocular TherapeutixSEC Form 42 February 2024Common Stock · traded 31 January 2024 · filed 2 February 2024
- ▼ sold on the open market 6,476 shares of Ocular TherapeutixSEC Form 48 February 2023Common Stock · traded 6 February 2023 · filed 8 February 2023
- was granted 166,667 shares of Ocular Therapeutix (a derivative holding)SEC Form 41 February 2023Stock Option (Right to Buy) · traded 30 January 2023 · filed 1 February 2023
- was granted 55,556 shares of Ocular TherapeutixSEC Form 41 February 2023Common Stock · traded 30 January 2023 · filed 1 February 2023
- was granted 166,667 shares of Ocular Therapeutix (a derivative holding)SEC Form 47 February 2022Stock Option (Right to Buy) · traded 3 February 2022 · filed 7 February 2022
- was granted 55,556 shares of Ocular TherapeutixSEC Form 47 February 2022Common Stock · traded 3 February 2022 · filed 7 February 2022
- was granted 190,000 shares of Ocular Therapeutix (a derivative holding)SEC Form 419 February 2021Stock Option (Right to Buy) · traded 17 February 2021 · filed 19 February 2021
- was granted 215,000 shares of Ocular Therapeutix (a derivative holding)SEC Form 43 February 2020Stock Option (Right to Buy) · traded 30 January 2020 · filed 3 February 2020
- ▲ bought on the open market 2,500 shares of Ocular TherapeutixSEC Form 417 June 2019Common Stock · traded 14 June 2019 · filed 17 June 2019
- was granted 150,000 shares of Ocular Therapeutix (a derivative holding)SEC Form 44 January 2019Stock Option (Right to Buy) · traded 2 January 2019 · filed 4 January 2019
- ▲ bought on the open market 12,500 shares of Ocular TherapeutixSEC Form 415 August 2018Common Stock · traded 14 August 2018 · filed 15 August 2018
- was granted 83,500 shares of Ocular Therapeutix (a derivative holding)SEC Form 42 February 2018Stock Option (Right to Buy) · traded 31 January 2018 · filed 2 February 2018
- ▲ bought on the open market 4,800 shares of Ocular TherapeutixSEC Form 48 December 2017Common Stock · traded 7 December 2017 · filed 8 December 2017
- was granted 125,000 shares of Ocular Therapeutix (a derivative holding)SEC Form 43 October 2017Stock Option (Right to Buy) · traded 2 October 2017 · filed 3 October 2017
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.